Radioimmunometric Assay to measure Anti-SARS-COV2 Antibodies in Serum

Unaltered image by Marco Verch


Available for Licensing and Collaboration

IP Status

US Utility Patent Pending (Not Yet Published)


​Torrance “Terry” M Nett
Eric Weber

At A Glance 

Researchers at Colorado State University have developed a radioimmunometric assay (RIA) to detect and quantitate antibodies against SARS-COV2 in serum.

For more details please contact our office.

Licensing Director

Steve Foster

Reference No.: 2020-110

Technology Highlights
  • Assay is an offshoot of the classic double antibody radioimmunoassay
  • Directly measure the amount of radiolabeled pathogen-specific antigen that is bound in immune complexes following the addition of a serum sample
  • Not only can detect the presence of pathogen-specific antibodies, but can quantitate the concentration in serum
  • Developing detection using assay with sputum (to avoid invasive blood draws)
  • Assay will be validated under guidance of the FDA (EUA)
  • High sensitivity – see Figure 1 below 

Figure 1:

Five samples were analyzed at a dilution of 1:10. The % binding vs the log PRNT90 (antibody titer) were graphed, showing a correlation between the PRNT90 and % binding of r = 0.98

  • More sensitive than other types of assays
  • Can quantify antibody concentration
  • Cost is significantly less than ELISA assays
  • Clinical Labs with RIA capabilities
  • Pharma and University Research

Last updated: June 2020

Add keywords or various names of inventors here (text is hidden)